Femasys Inc. posted an updated corporate presentation on its website on May 13, 2026, to be used in investor meetings, highlighting its women's health portfolio including fertility products and FemBloc permanent birth control.
Key takeaways
Posted updated corporate presentation (Exhibit 99.1) on website for use in investor, analyst meetings.
Features multi-asset women's health portfolio: fertility family (FemaSeed, FemVue, FemSperm, SpermVue), FemBloc (EU approved, U.S. trial), FemCerv diagnostic.
FemaSeed shows 2x pregnancy rate vs. IUI in clinical trial for low sperm count cases.
FemBloc targets non-surgical permanent birth control amid ~13M U.S. women done having children.